Provectus Pharmaceuticals has announced the commencement of Phase 1 study of PV-10 injection to elucidate bystander effect at the Moffitt Cancer Center. The study is designed to assess the possible immune biomarkers in both tumor tissue ...
Tags: Provectus, injection, immune biomarkers, PV 10 injection